Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation
Open Access
- 20 May 2023
- journal article
- research article
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (2) , 27-34
Abstract
Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs of various pharmaceutical groups are used for pain management and administered subsequentially in accordance with the pain intensity visual analogue scale. For moderate and severe pain syndrome, opioid analgesics are used which have side effects limiting their use in some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence of accumulation which makes its safety profile favorable. Pronounced analgesic effect of tafalgin, as well as ease of administration and absence of significant adverse events, allow to significantly improve the quality of life of patients with chronic pain syndrome.Keywords
This publication has 11 references indexed in Scilit:
- Практические рекомендации по лечению хронического болевого синдрома у взрослых онкологических больныхMalignant tumours, 2022
- A clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer painJournal of Modern Oncology, 2022
- Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trialsHead and Neck Tumors (HNT), 2022
- The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trialP.A. Herzen Journal of Oncology, 2022
- Pain Management in Patients with Multiple Myeloma: An UpdateCancers, 2019
- Clinical characteristics of pain syndrome in patients with multiple myelomaS.S. Korsakov Journal of Neurology and Psychiatry, 2016
- Neurologic aspects of plasma cell disorders2014
- Pain management in multiple myelomaExpert Review of Anticancer Therapy, 2010
- Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignanciesOral Oncology, 2008
- Paraproteinemic NeuropathiesBrain Pathology, 2001